

**IN THE CLAIMS:**

The pending claims are reiterated for the convenience of the Examiner.

Please cancel claims 25 and 26.

Please amend the claims as follows:

22. (Amended) A method for ameliorating [diseases characterized by] a cell proliferative disorder associated with CTGF, [which] compris[es]ing treating a subject having the disorder, at the site of the [disease] disorder, with a therapeutically effective amount of a composition containing an antibody that binds to CTGF [reactive agent] or fragments thereof, and that does not bind to PDGF or fragments thereof.

23. (Reiterated) The method of claim 22, wherein the cell proliferative disorder is due to overgrowth of cells.

24. (Reiterated) The method of claim 22, wherein the cell proliferative disorder is due to overgrowth of connective tissue cells.

25. (Canceled) The method of claim 22, wherein the CTGF reactive agent is an antagonist of CTGF.

26. (Canceled) The method of claim 25, wherein the antagonist is the antibody of claim 14.

27. (Reiterated) The method of claim 22, wherein the cell proliferative disorder is due to an undergrowth of cells.

**IN THE SPECIFICATION**

On page 1, before line 1, please delete lines 3-5 and replace with --This is a divisional of application

Serial No. 08/167,628 filed December 14, 1993, now U.S. Patent No. 5,408,040, *which is a continuation of application Serial No. 07/752427 filed 8/30/91, now abandoned.*

38